Related Experiment Videos
Current biological therapies for inflammatory bowel disease
Daniel C Baumgart1, Axel U Dignass
1Charité Medical Center - Virchow Hospital, Medical School of the Humboldt-University, Department of Medicine, Division of Hepatology & Gastroenterology, D-13344 Berlin, Germany. daniel.baumgart@charite.de
Current Pharmaceutical Design
|December 8, 2004
Summary
Biological therapies for inflammatory bowel disease (IBD) have advanced significantly. This review covers novel biologic agents and their mechanisms, suggesting an increasing role for biologics in IBD management.
Area of Science:
- Immunology
- Gastroenterology
- Pharmacology
Background:
- Understanding of the human intestinal immune system and inflammatory bowel disease (IBD) has grown exponentially.
- Advances stem from clinical data and genetically engineered animal models, fueling interest in novel therapeutics.
- The past decade has seen significant progress in unraveling the complexities of intestinal inflammation.
Purpose of the Study:
- To review the mechanisms of various biologic agents used in IBD treatment.
- To summarize available data on investigational and approved biologic agents for IBD.
- To discuss the potential future role of biologics in managing IBD.
Main Methods:
- Literature review of current biological therapies for inflammatory bowel disease.
- Discussion of mechanisms including antibodies against pro-inflammatory cytokines, T-cell antibodies, and adhesion molecule blockers.
- Summary of data on approved and investigational agents, including probiotics and extracorporeal immunomodulation.
Main Results:
- Biologics encompass a wide range of agents targeting specific inflammatory pathways.
- Investigational and approved agents show promise in managing IBD.
- Probiotics and extracorporeal immunomodulation are also discussed as adjunctive therapies.
Conclusions:
- Biologic therapies represent a rapidly advancing frontier in IBD treatment.
- The diverse mechanisms of action offer targeted approaches to inflammation control.
- Biologics are poised to play an increasingly significant role in the management of inflammatory bowel disease.